The Advisory Committee on Immunization Practices of the US Centers for Disease Control and Prevention has recommended the routine usage of Bavarian Nordic’s mpox vaccine, Jynneos, in adults.
The two-dose vaccine regimen is indicated for use in those aged 18 years and above with specific mpox infection risk factors.
The committee had previously recommended the use of Jynneos in people at risk of infection only at the time of an outbreak.
Bavarian Nordic president and CEO Paul Chaplin stated: “Since the outbreak of mpox last year, Bavarian Nordic has supplied millions of doses of our vaccine to more than 70 countries worldwide, which has had a positive impact on controlling this unprecedented outbreak of mpox.
“The broadened ACIP recommendation recognises the significance of maintaining a high awareness of the disease among risk groups and the importance of ensuring broader access to the vaccine beyond an outbreak situation.”
Subject to obtaining approval for the modified recommendations, the company plans to make Jynneos commercially available in the US in the first half of 2024.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Jynneos received FDA approval in 2019.
In August 2023, Bavarian Nordic received a $120m US Biomedical Advanced Research and Development Authority contract to produce smallpox/mpox vaccine in bulk.
In 2022, the Standing Committee for Vaccination in Germany recommended the vaccine use in adults at risk.
The European AIDS Clinical Society subsequently recommended Jynneos use in adult HIV patients, or in those receiving pre-exposure prophylaxis treatment.
Source link
#recommends #Bavarian #Nordics #mpox #vaccine #routine
